This course is part of the Where Are We Now? The Integral Role of GLP-1 RAs in the Treatment of Type 2 Diabetes Mellitus curriculum.
Virtual CME Program
1.00 CME/CE Credit
Where Are We Now? The Integral Role of GLP-1 RAs in the Treatment of Type 2 Diabetes Mellitus
GLP-1 RAs have now been on the market for some time, yet they remain underutilized in primary care. This session will not only review recent evidence of the manifold benefits of GLP-1 RAs, but it will also use a patient case to illustrate the obstacles PCPs experience in prescribing these important agents—and how to overcome them!
- Review the mechanism of action (MOA), administration, and indications of the various glucagon-like peptide-1 receptor agonists (GLP-1 RA) available for the treatment of type 2 diabetes mellitus (T2DM)
- Describe the data from clinical trials showing the benefits of GLP-1 RA including those beyond glycemic control
- Summarize guidelines around the use of GLP-1 RA, highlighting recent changes which encourage earlier initiation in diabetes care and consideration of comorbidities
- Outline how to use patient-centered care to approach common barriers in developing and adjusting a diabetes care management plan
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC
President and Owner
Diabetes Consulting Services
North Bethesda, MD
Tina K. Thethi, MD, MPH
Associate Investigator and Endocrinologist
AdventHealth Translational Research Institute
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Lucia M. Novak, MSN, ANP-BC, BC-ADM: Speaker for Abbott Diabetes Care; Boehringer Ingelheim, Lilly, Novo Nordisk, Xeris; Advisor for Abbot Diabetes Care; Provention Bio; Novo Nordisk; Xeris; Consultant for Abbott Diabetes Care; Novo Nordisk, Xeris.
Tina K. Thethi, MD, MPH: Speaker for Novo Nordisk.
Pamela Kushner, MD, FAAFP (moderator): Speaker for Novo Nordisk, Janssen, Lilly, Boehringer Ingelheim, AstraZeneca, Bayer, GlaxoSmithKline. Advisor for Novo Nordisk, Janssen, Lilly, Boehringer Ingelheim, AstraZeneca, Abbott, Intuity, Phathom, Pfizer. Consultant for Novo Nordisk, Janssen, Lilly, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline
Moderators and non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
AMA PRA Category 1 Credits
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education. Provider number: 040308.
This activity is approved for 1.00 contact hour of continuing education, which includes 1.00 hours of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Supporters and Partners
Novo Nordisk Inc.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email email@example.com or call (877) 477-4633.